Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.

You may also be interested in...



CMS’ McClellan To Discuss Medicare Rx With AARP Board Feb. 1

Agency chief will address the organization’s annual policy meeting less than two weeks after release of the final rules implementing Part D drug benefit. HHS Information Technology Coordinator Brailer is expected to discuss the e-prescribing draft rule.

CMS’ McClellan To Discuss Medicare Rx With AARP Board Feb. 1

Agency chief will address the organization’s annual policy meeting less than two weeks after release of the final rules implementing Part D drug benefit. HHS Information Technology Coordinator Brailer is expected to discuss the e-prescribing draft rule.

CMS Claims Too Much Authority Over Medicare Rx Prices – PhRMA

The Centers for Medicare & Medicaid Services incorrectly interprets the Medicare Modernization Act to allow "justification of aggregate price levels for groups of drugs," PhRMA asserts in comments on CMS' proposed Part D regs.

Related Content

Topics

UsernamePublicRestriction

Register

PS060925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel